Oropharyngeal and otorhinological changes in end stage renal patients undergoing hemodialysis

Ola M. Ezzatt 1, Mohamed G. Hamed 2, Yasmine Gamal 3

1 Associate professor in department of Oral Medicine, Periodontology, Oral Diagnosis and Radiology, Faculty of Dentistry, Ain Shams University, Cairo, Egypt
2 Assistant professor in department of Otorhinolaryngology, Faculty of Medicine, Helwan University and ENT consultant in Arayah Hospital in Maadi, Cairo, Egypt
3 Lecturer in department of Oral Medicine, Periodontology and Oral Diagnosis. Faculty of Dentistry, Modern University of Information and Technology (MTI). Cairo, Egypt

Correspondence:
Department of Oral Medicine
Periodontology, Oral Diagnosis and Radiology
Faculty of Dentistry, Ain Shams University
20 Organization of African Union St.
Cairo, 1156, Egypt
dr.ola@dent.asu.edu.eg

Received: 02/02/2021
Accepted: 16/04/2021

Abstract
Background: The study aimed to assess oropharyngeal and otorhinolaryngological changes in end stage renal disease (ESRD) patients undergoing hemodialysis and correlate the findings to renal functions.
Material and Methods: This case-control study compared oral and otorhinolaryngological findings in 85 patients with (ESRD) on maintenance hemodialysis to age and sex matched 85 healthy controls. Frequencies of findings were calculated and compared and correlation between biochemical and the oral health parameters in case group was determined using T-test, chi-square and Pearson correlation test (significance were set at \( P<0.05 \)).
Results: The frequency of oral signs and mucosal symptoms were significantly higher among ESRD compared to healthy controls. Dry mouth (34.12%), bad odour (32.94%), increased tongue coating (50.59%) and pale mucosa (45.88%) were the most commonly reported. Otorhinolaryngological findings was higher in cases than in controls, with otomycosis (10.59%) and allergic rhinitis (5.88%) being the most frequent findings. Serum creatinine and blood urea mean levels were higher in ESRD patients with oral and otorhinolaryngological findings compared to those without findings.
Conclusions: Oral and nasal manifestations in patients with ESRD on maintenance hemodialysis were significantly higher in comparison to healthy individuals and were related to their serum creatinine and blood urea mean levels.

Key words: Chronic kidney disease, renal dialysis, Oral manifestation, nasal, case control, Egypt.
Introduction
The sequelae of primary renal disease or systemic diseases with renal involvement with loss of kidney function is a final syndrome called End Stage Renal Disease (ESRD), characterized by profound alteration of water, electrolyte, and acid-base homeostasis, as well as retention of uremic toxins, especially protein catabolism nitrogen waste products (1).

Various signs and symptoms are presented in patients with ESRD, reflecting the improper kidney’s functions (2), or adverse drug reactions in every organ system (3). A wide variety of oropharyngeal manifestations and symptoms have been documented in these patients by several authors including halitosis, xerostomia, periodontitis, dysgeusia, candidiasis, parotitis, abnormal lip pigmentation, burning mouth sensation and ulcerations (4-6). Determination and identification of these changes in the oral cavity will improve the quality of life in these patients. Furthermore, it is important to consider patients with ESRD on maintenance hemodialysis (HD) as a candidate of renal transplant in the future. Since the availability of the transplant is unpredictable, and when it occurs the time interval of pretransplant preparation is too short to manage all the existing oral infections in HD patients, therefore, it is worth to evaluate and maintain an acceptable oral health status of these dialysis patients at least until successful transplantation (7).

The most commonly analyzed abnormalities in head and neck area in patients with chronic kidney diseases (CKD), were sensorineural hearing loss, epistaxis, candidiasis, halitosis, xerostomia, dysgeusia, lip and thyroid cancers (8).

The study aimed to investigate the prevalence of oropharyngeal changes and otorhinolaryngological changes in Egyptian hemodialysis patients compared to healthy individuals; and to assess possible association between subjective symptoms and objective clinical findings and serum urea and creatine levels.

Material and Methods

- Study design: It is a case-control observational single center study.
- Sample size estimation: It was anticipated that the prevalence of oral lesions cases among chronic kidney diseases case group was 96.7% and that the prevalence in the healthy control group was 16.7% as reported by Oyetola et al. (9) The minimum required sample size per group was calculated to be 71 participants using EpiTools web-based application at (https://epitools.ausvet.com.au/casecontrols?case=case-controlSS) assuming relative risk of (5.8) with the standard normal values set at 0.05, a power of 90 % and a case–control ratio of 1:1. Considering about 20 % sample attrition; we included 170 participants (85 patients with chronic kidney diseases undergoing hemodialysis and 85 matched healthy controls).
- Subjects: A total of 170 adult participants of both genders above 18 years were included in the study. 85 patients were recruited for cases group from consecutive inpatients diagnosed by end-stage renal failure regardless of the etiology of the condition and regularly attending the nephrology hemodialysis department for more than three months at (Arayah Hospital in Maadi, Cairo, Egypt). Participants with history of smoking (cigarette, pipe or water pipe) or alcoholic patients in the last 10 years were excluded.

The control group populations were randomly recruited from (Out-patient dental clinic and ENT clinic at (Arayah Hospital in Maadi, Cairo, Egypt) to include total 85 clinically healthy participants, with no history of kidney disease, or any other chronic debilitating illness, or habit of smoking or drinking, and/or not receiving any medication that could affect oral health. Participants with history of excessive or chronic noise exposure, congenital ear deformities, otological trauma or surgery have been excluded from both groups.
- Ethics approval and consent to participate: This study was conducted in full accordance with the World Medical Association Declaration of Helsinki. The brief explanation of the purpose of the study, the optional contribution with confidentiality and sole use of the information for the mentioned purpose was ensured. All subjects were informed about the procedure and their agreements were taken by signing the informed consent.

- Data collection: For eligible participants full medical records were reviewed including last measured serum creatinine and urea levels in cases group. Data recording and examination were performed at the bed side during hemodialysis session for patients' convenience. Detailed intraoral examination for the entire oral and pharyngeal mucosal surfaces. Signs and symptoms identification were objectively searched for, and /or reported by the patients for any mucosal changes using simple disposable dental examination instruments. Oropharyngeal lesions were diagnosed and documented according to the history and clinically accepted criteria based on the WHO Guide to Epidemiology and Diagnosis of Oral Mucosal Diseases. Otorhinolaryngological dysfunctions were assessed and recorded by the ENT specialist (ear examination by inspection, palpation and otoscopic examination. Hearing assessment by tuning fork test and suspected hearing loss patients were subjected to pure tone audiometry and tympanometry. Nasal, pharyngeal and laryngeal examination was performed using simple outpatient clinic tools.

- Statistical analysis: Data was collected, tabulated and then subjected to the statistical analysis using the Statistical Package for Social Sciences (SPSS) (version 13.0 for windows, SPSS Inc., Chicago, IL, USA). The quali-
tative presented as numbers and percentages. The oral and otorhinolaryngological health data from the dialysis patients was compared to those from matched control group using independent Student t-tests, chi-square tests or Fisher’s exact tests when appropriate. The Pearson correlation was determined between biochemical and the oral health parameters in case group. All levels of significance were set at $P<0.05$.

**Results**

One hundred and seventy subjects participated in the study, 86 (50.59%) males and 84 (49.41%) females with age ranged from 18-78 years. The participants in cases and control group were matched for age and sex distribution with no statistically significant differences ($p=0.53$). The duration of the end stage renal diseases in subject undergoing hemodialysis ranged from 2 to 120 months and it was significantly correlated to patient age ($P$-value=0.026).

The most common cause of (ESRD) among patients was chronic glomerulonephritis (54.12%), followed by diabetic nephropathy (16.47%), while the remaining subjects reported other causes like hypertensive nephropathy or the cause was unknown. Combined anemia, diabetes and hypertension was reported in 31.76% of cases and 51.76% of patients were under antihypertensive medications while 43.53% were on calcium-carbonate supplementation. Considerable percentages of patients were taking antiplatelet, antidiabetic, multivitamins or diuretics (Table 1).

| Medical characteristic | Mean (SD) | Range |
|------------------------|-----------|-------|
| Duration of ESRD (Months) | 39.1 (33.0) | 2 - 120 |
| Serum Creatinine level (mg/dl) | 7.01 (1.3) | 5 - 10.9 |
| Blood Urea level (mg/dl) | 86.01 (27.8) | 55 - 166 |

Values of frequency are given as number and percentage [N (%)]. Values of laboratory levels and durations are presented as mean and standard deviation [Mean (SD)].

The frequency of oral signs and mucosal symptoms were higher among ESRD compared to healthy control subjects and the differences were statistically significant (Table 2). Dry mouth (34.12%) and bad odour (32.94%) were the most commonly reported symptoms followed by unpleasant taste and burning sensation, while increased tongue coating (50.59%) and pale mucosa (45.88%) followed by petechiae/ecchymosis, uremic stomatitis, dry fissured tongue and mucosal hyperpigmentation were the most frequent oral findings among ESRD (Fig. 1).

Prevalence of otorhinolaryngological and pharyngeal signs and dysfunctions were higher in cases than in control group however the differences were not statistically significant except with nasal findings ($P$-value=0.025). (Table 3). Bilateral otomycosis (10.59%) and allergic rhinitis (5.88%) were the most commonly reported ear and nasal findings respectively while 28.24% of subjects were difficult to be examined for laryngeal signs. Uremic stomatitis was associated with highest urea and creatinine level, while bad odour was frequent among those with low serum creatinine levels and burning sensation among those with lowest blood urea levels (Fig. 2).

Serum creatinine and blood urea mean levels were higher in ESRD patients with oral and otorhinolaryngological findings compared to those without findings however the difference was significant only regarding creatinine level (Table 4).
Table 2: Comparison of frequency of oral signs, mucosal symptoms, periodontal and dental manifestations among end stage renal diseases patients undergoing hemodialysis (ESRD) and healthy control subjects.

| Oral Findings          | All (N=170) | (%) | Cases (N=85) | (%) | Control (N=85) | (%) | P-value |
|------------------------|-------------|-----|--------------|-----|---------------|-----|---------|
| **Oral Symptoms**      |             |     |              |     |               |     |         |
| Dry mouth              | 34          | (20.0) | 29 | (34.12) | 5 | (5.88) | <0.00001*** |
| Bad odor               | 30          | (17.65) | 28 | (32.94) | 2 | (2.35) | <0.00001*** |
| Unpleasant taste       | 30          | (17.65) | 23 | (27.06) | 7 | (8.24) | 0.002**  |
| Burning sensation      | 17          | (10.0) | 13 | (15.29) | 4 | (4.71) | 0.038*   |
| Total with no oral symptoms | 70      | (41.18) | 3 | (3.53) | 67 | (78.82) | <0.00001*** |
| Total with oral symptoms | 100    | (58.82) | 82 | (48.24) | 18 | (10.59) |         |
| **Oral Signs**         |             |     |              |     |               |     |         |
| Pale mucosa            | 45          | (26.47) | 39 | (45.88) | 6 | (7.06) | <0.00001*** |
| Increased tongue coating | 48      | (28.24) | 43 | (50.59) | 5 | (5.88) | <0.00001*** |
| Petechiae/ecchymosis   | 18          | (10.59) | 17 | (20.0) | 1 | (1.18) | 0.0001**  |
| Uremic stomatitis      | 10          | (5.88) | 10 | (11.76) | 0 | (0) | 0.0007**  |
| Dry fissured tongue    | 14          | (8.24) | 12 | (14.12) | 2 | (2.35) | 0.009**  |
| Hyperpigmentation      | 20          | (11.76) | 15 | (17.65) | 5 | (5.88) | 0.03*    |
| Denture granuloma      | 4           | (2.35) | 4 | (4.71) | 0 | (0) | 0.12     |
| Leukoplakia            | 6           | (3.53) | 5 | (5.88) | 1 | (1.18) | 0.21     |
| **Oral Candidiasis**   | 17          | (10.0) | 6 | (7.06) | 11 | (12.94) | 0.3      |
| Lichen Planus          | 3           | (1.76) | 2 | (2.35) | 1 | (1.18) | 0.62     |
| Traumatic Ulcer        | 3           | (1.76) | 2 | (2.35) | 1 | (1.18) | 0.62     |
| Frictional Keratosis   | 6           | (3.53) | 4 | (4.71) | 2 | (2.35) | 0.68     |
| Aphthous ulcer         | 12          | (7.06) | 7 | (8.24) | 5 | (5.88) | 0.76     |
| Normal variants        | 8           | (4.71) | 5 | (5.88) | 3 | (3.53) | 0.71     |
| Others (Hypopigmentation) | 2      | (1.18) | 1 | (1.18) | 1 | (1.18) | 1        |
| Total with no oral signs | 47      | (27.65) | 3 | (3.53) | 44 | (51.76) | <0.00001*** |
| Total with oral signs  | 123         | (72.35) | 87 | (70.07) | 36 | (29.26) |         |
| **Periodontal manifestations** |             |     |              |     |               |     |         |
| Periodontitis          | 16          | (9.41) | 9 | (10.59) | 7 | (8.24) | 0.79     |
| Gingival enlargement   | 17          | (10.0) | 11 | (12.94) | 6 | (7.06) | 0.30     |
| Dental manifestations  |             |     |              |     |               |     |         |
| Decayed >10            | 32          | (18.82) | 20 | (23.53) | 12 | (14.12) | 0.08*    |
| Missed > 10            | 51          | (30.0) | 33 | (38.82) | 18 | (21.18) | 0.89     |
| Enamel Hypoplasia      | 6           | (3.53) | 5 | (5.88) | 1 | (1.18) | 0.21     |

Frequencies are given as number (N) and Percentage (%). *Significant at $p \leq 0.05$ compared to control group (Fisher’s exact test).

Discussion
The present study revealed significantly higher prevalence of oral symptoms (48.24%) and lesions (70.07%) as well as otorhinolaryngological findings (29.41%) in ESRD patients undergoing hemodialysis in comparison to healthy individuals. These findings were generally reported in other studies (8-10) and among other populations (11), which could be related to the medical, psychological, or socioeconomic characteristics of these patients (12). Our data revealed highest prevalence of dry mouth (34.12%) among the reported oral symptoms which was in agreement with the 32.9% to 68% figures reported in other studies of dialysis patients (13-15). Dry mouth
Fig. 1: Photographs of oral findings in hemodialysis group of patients including increased tongue coating (a) and pale mucosa (b).

Table 3: Comparison of frequency of pharyngeal and otorhinolaryngological signs and dysfunctions among end stage renal disease patients undergoing hemodialysis (ESRD) and healthy control subjects.

| Otorhinolaryngological and pharyngeal Signs and dysfunctions | All (N=170) | Cases (N=85) | Control (N=85) | P-value |
|--------------------------------------------------------------|-------------|--------------|----------------|---------|
| Ear Findings                                                 |             |              |                |         |
| Bilateral otomycosis                                         | 10 (5.9%)   | 9 (10.59%)   | 3 (1.18%)      | 0.329   |
| Chronic suppurative otitis media                             | 3 (1.8%)    | 2 (2.35%)    | 1 (1.18%)      | 0.623   |
| Bilateral wax                                                | 15 (8.8%)   | 7 (8.24%)    | 6 (7.06%)      | 0.590   |
| Sensory neural hearing loss                                   | 5 (2.9%)    | 4 (4.71%)    | 1 (1.18%)      | 0.368   |
| Otitis externa                                               | 2 (1.2%)    | 1 (1.18%)    | 1 (1.18%)      | 1       |
| Tympanic membrane perforation                                 | 1 (0.6%)    | 1 (1.18%)    | 0 (0)          | 1       |
| Bilateral crusts                                              | 1 (0.6%)    | 1 (1.18%)    | 0 (0)          | 1       |
| Total subjects with ear findings                              | 37 (21.8%)  | 25 (29.41%)  | 12 (14.12%)    | 0.025*  |
| Total subjects free of ear findings                          | 133 (78.2%) | 60 (70.59%)  | 73 (85.88%)    |         |
| Nasal Findings                                               |             |              |                |         |
| Allergic rhinitis                                            | 8 (4.7%)    | 5 (5.88%)    | 3 (3.53%)      | 0.720   |
| Acute sinusitis                                              | 2 (1.2%)    | 1 (1.18%)    | 1 (1.18%)      | 1       |
| Allergic sinusitis                                           | 5 (2.9%)    | 2 (2.35%)    | 3 (3.53%)      | 0.684   |
| Atrophic rhinitis                                            | 3 (1.8%)    | 2 (2.35%)    | 1 (1.18%)      | 1       |
| Nasal polypi                                                 | 3 (1.8%)    | 2 (2.35%)    | 1 (1.18%)      | 1       |
| Vestibulitis                                                 | 1 (0.6%)    | 1 (1.18%)    | 0 (0)          | 1       |
| Hypertrophic rhinitis                                        | 5 (2.9%)    | 2 (2.35%)    | 3 (3.53%)      | 1       |
| Chronic sinusitis                                            | 6 (3.5%)    | 2 (2.35%)    | 4 (4.71%)      | 0.682   |
| Total subjects with nasal findings                           | 33 (19.4%)  | 17 (20%)     | 16 (18.82%)    | 0.695   |
| Total subjects free of nasal findings                        | 121 (71.2%) | 68 (80%)     | 53 (62.35%)    |         |
| Laryngeal findings                                           |             |              |                |         |
| Chronic laryngitis                                           | 3 (1.76%)   | 2 (2.35%)    | 1 (1.18%)      | 0.623   |
| Vocal fold oedema                                            | 3 (1.76%)   | 2 (2.35%)    | 1 (1.18%)      | 0.623   |
| Vocal cord nodule                                            | 2 (1.18%)   | 1 (1.18%)    | 1 (1.18%)      | 1       |
| Vocal cord paralysis                                         | 2 (1.18%)   | 1 (1.18%)    | 1 (1.18%)      | 1       |
| Total subjects difficult to examine                          | 36 (21.18%) | 24 (28.24%)  | 12 (14.12%)    | --      |
| Total subjects with laryngeal findings                       | 10 (5.88%)  | 6 (7.06%)    | 4 (4.71%)      | 0.518   |
| Total subjects free of laryngeal findings                    | 122 (71.76%)| 57 (67.06%)  | 65 (76.47%)    |         |

Frequencies are presented as number (N) and percentage (%), *Significant at p≤0.05 compared to control group (Fisher’s exact test).
Fig. 2: A bar graph showing comparison between serum and creatinine levels among ESRD patients manifested with oral signs and symptoms.

Table 4: Serum creatinine and blood urea level relation to presence of oral or otorhinolaryngological findings.

| Biochemical level | In ESRD with lesions | In ESRD without lesions | P-value |
|-------------------|----------------------|-------------------------|---------|
| Serum Creatinine level |                      |                         |         |
| (Oral)            | 10.03 (1.6)          | 7.8 (2.7)               | < 0.0001* |
| (Otorhinolaryngological) | 9.42 (2.1)          | 8.2 (1.3)               | 0.0018*  |
| Blood Urea level  |                      |                         |         |
| (Oral)            | 90.32 (21.57)        | 76.67 (24.67)           | 0.2617  |
| (Otorhinolaryngological) | 82.12 (16.12)        | 78.38 (26.52)           | 0.4998  |

Values of laboratory levels are presented as mean and standard deviation [Mean (SD)], *Significant at \( p \leq 0.05 \) (Independent t-test).

in ESRD patients may be a multifactorial phenomenon; mouth breathing and medication use (13), water restriction, low saliva flow, minor salivary glands parenchymal fibrosis and atrophy (15), being identified factors (14). Bad odor and unpleasant taste as frequently reported symptoms may be attributed to increased levels of urea in the blood and also in the saliva, which turn into ammonia by the action of urase-splitting oral organism and exaggerated by xerostomia (16). Contrary to previous researches that showed removal of urea and other toxin via dialysis results in improved taste function (17,18). This, could be related to low animal proteins intake, low zinc levels, increased phosphate concentrations or changes in saliva pH, which led to unpleasant or metallic taste. The occurrence of burning sensation reached 15.29% of all patients. This result was fairly similar to that reported by Nandan et al. (13).

Our results revealed that the most frequent oral lesions among ESRD patients were pale oral mucosa (45.88%) and increased tongue coating (about 50.59%), gingival enlargement and uremic stomatitis. These results were higher than that reported by de la Rosa-Garca (19), and Chuang et al. (20), and lower than that reported by Anuradha et al. (21).

Increased tongue coatings probably caused by retention of desquamated epithelial cells and by volatile sulfurous compounds produced by anaerobic bacteria on the tongue surfaces. Poor oral hygiene, low saliva flow and even emotional condition of the dialysis patients have an impact on its occurrence.

The appearance of pale oral mucosa in ESRD patients explained mainly by anemia caused by erythropoietin and folic acid deficiencies (22). Pale mucosa has also been associated to malnutrition (23). Moreover, the ye-
Illowish mucosa discoloration may be caused by urocromo pigments (22).

Uremic stomatitis was found on 11% of ESRD patients. The lesion has been described as localized or generalized burning oral mucosa with erythematous areas covered by a grayish pseudomembranous exudate leaving, on removal, an intact (type I) or ulcerated (type II), often coexisting with candidiasis (24). Its etiology is unknown. It has been considered the reaction to an irritant; possibly ammonia compounds derived from urea hydrolysis by salivary urease, whenever saliva urea concentration exceeds 180 mg/dl (24). Uremic stomatitis was associated with highest serum urea and creatinine level in our study probably as a result of a high urea concentration in saliva, and its conversion to ammonia. However, the lesion considered uncommon because of usually earlier dialysis therapy and that is why we found only few cases, just starting dialysis therapy, with oral lesion matching uremic stomatitis description.

Salivary and serum creatinine and urea levels in patients with chronic kidney disease are positively correlated which could be responsible for the complaints of dry mouth (2), mouth odour or uremic breath (20), as well as tongue coating and other oral complications in these patients (19). However, in the present study bad odour was most frequent among those with low serum creatinine levels and burning sensation among those with lowest blood urea levels. Additional possible causes are changes in saliva pH, which might explain a metallic or unpleasant taste (25).

The study was limited by single center sampling and lack of salivary biochemical analysis, however frequent oropharyngeal changes and otolaryngological dysfunctions were identified among this cohort of end stage renal disease patients undergoing with controlled socioeconomic confounding factors. Implementing therapeutic and preventive measures for those patients regarding these findings would be clinically relevant.

References

1. Georgakopoulou EA, Achtari MD, Afentoulide N. Dental management of patients before and after renal transplantation. Stomatologija. 2011;13:107-12.
2. Summers SA, Tilakaratne WM, Fortune F, Ashman N. Renal Disease and the Mouth. Am J Med. 2007;120:565-73.
3. Anuradha BR, Katta S, Kode VS, Praveena C, Sathe N, Sandeep N, et al. Oral and salivary changes in patients with chronic kidney disease: A clinical and biochemical study. J Indian Soc Periodontol. 2015;19:297-301.
4. Bots C, Poorterman I, Brand H, Kalsbeek H, Amerongen B, Veerman E, et al. The oral health status of dentate patients with chronic renal failure undergoing dialysis therapy. Oral Dis. 2006;12:176-80.
5. Kho HS, Lee SW, Chung SC, Kim YK. Oral manifestations and salivary flow rate, pH, and buffer capacity in patients with end-stage renal disease undergoing hemodialysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:316-9.
6. Tadakamadla J, Kumar S, Mamatha GP. Comparative evaluation of oral health status of chronic kidney disease (CKD) patients in various stages and healthy controls. Spec Care Dentist. 2014;34:122-6.
7. Chen LP, Chiang CK, Chan CP, Hung KY, Huang CS. Does Periodontitis Reflect Inflammation and Malnutrition Status in Hemodialysis Patients? Am J Kidney Dis. 2006;47:815-22.
8. Krajewska Wojciechowska J, Krajewski W, Zatoński T. Otorhinolaryngological dysfunctions induced by chronic kidney disease in pre- and post-transplant stages. Eur Arch Otorhinolaryngol. 2020;277:1575-91.
9. Oyetola EO, Owotade FJ, Aghbelusi GA, Fatusi OA, Sanusi AA. Oral findings in chronic kidney disease: implications for management in developing countries. BMC Oral Health. 2015;15:24.
10. Honarmand M, Farhad-Mollashahi L, Nakhae A, Sargolzaie F. Oral manifestation and salivary changes in renal patients undergoing hemodialysis. J Clin Exp Dent. 2017;9:207-10.
11. Ruospo M, Palmer SC, Craig JC, Gentle G, Johnson DW, Ford PJ, et al. Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. Nephrol Dial Transplant. 2014;29:364-75.
12. Souza CM, Brasoi AP, Luczyszyn SM, Casagrande RW, Pecuits-Filho R, Riella MC, Ignácio SA, Trevilatto PC. Oral health in Brazilian patients with chronic renal disease. Rev Med Chil. 2008;136:741-6.
13. Nandan RK, Sivapathasundaram B, Sivakumar G. Oral manifestations and analysis of salivary and blood urea levels of patients undergoing haemodialysis and kidney transplant. Indian J Dent Res. 2005;16;77-82.
14. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Chang HR. Decreased salivary function in patients with end-stage renal disease requiring hemodialysis. Am J Kidney Dis. 2006;38:1110-4.
15. Postorino M, Catalano C, Martorano C, Cutrupi S, Marino C, Cozzupoli P, et al. Salivary and lacrimal secretion is reduced in patients with ESRD. Am J Kidney Dis. 2003;42:722-8.
16. Khoezimeh F, Torabini N, Shahnaseri S, Shafae H, Mousavi SA. Determination of salivary urea and uric acid of patients with halitosis. Dent Res J (Isfahan). 2017;14:241-5.
17. Manley KJ. Saliva composition and upper gastrointestinal symptoms in chronic kidney disease. J Ren Care. 2014;40:172-9.
18. Middleton RA, Allman-Farinelli MA. Taste sensitivity is altered in patients with chronic renal failure receiving continuous ambulatory peritoneal dialysis. J Nutr. 1999;129:122-5.
19. de la Rosa García E, Mondragón Padilla A, Aranda Romo S, Bustamante Ramirez MA. Oral mucosa symptoms, signs and lesions, in end stage renal disease and non-end stage renal disease diabetic patients. Med Oral Patol Oral Cir Bucal. 2006;11:E467-73.
20. Chuang SF, Sung JM, Kuo SC, Huang JJ, Lee SY. Oral and dental manifestations in diabetic and non-diabetic uremic patients receiving hemodialysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:689-95.
21. Anuradha BR, Katta S, Kode VS, Praveena C, Sathe N, Sandeep N, et al. Oral and salivary changes in patients with chronic kidney disease: A clinical and biochemical study. J Indian Soc Periodontol. 2015;19:297-301.
22. Li T, Wilcox CS, Lipkowitz MS, Gordon-Cappelli J, Dragoi S. Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients. Am J Nephrol. 2019;50:411-21.
23. Leao JC, Gueiros LA, Segundo A V, Carvalho AA, Barrett W, Por ter SR. Uremic stomatitis in chronic renal failure. Clinics (Sao Paulo). 2005;60:259-62.
24. Epstein SR, Mandel I, Scopp Iw. Salivary Composition and Calcium Determination of salivary urea and uric acid of patients with halitosis. J Clin Exp Dent. 2021;13(7):e701-8.
25. Peyvandi A, Roozbahany NA. Hearing loss in chronic renal failure patient undergoing hemodialysis. Indian J Otolaryngol Head Neck Surg. 2013;65:S537-40.

Funding
This research received no specific grant from any funding agencies.

Ethics approval
This study was approved by the Faculty of Dentistry, Ain Shams University, Research Ethics Committee (FDASU-REC IR102002).

Authors' contributions
Ola M. Ezzatt contributed to study design, drafted the manuscript and contributed in data analysis, and interpretation. Mohamed G. Hamed contributed to the conception, data acquisition and interpretation and revised the manuscript. Yasmine Gamil contributed in study conception and implementation, data acquisition and data analysis.

Conflict of interest
No potential conflict of interest by any authors.